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Nikogosov et al. questions 2 main issues related to our APOE and 
COVID-19 letters (1,2). These focus on the initial candidate gene 
analysis reporting an association which was not genome-wide sig-
nificant, with the suggestion that this somehow undermines genome-
wide association studies (GWAS). Secondly, our choice of control 
group is questioned.
On the first issue, our work was undertaken after the COVID-
19 Host Genetics Initiative (https://www.covid19hg.org/) was set 
up to enable pooled GWAS analyses of COVID-19 host genetics. 
Given that dementia had emerged as a major risk factor for severe 
COVID-19 (3), we hypothesized that the dementia risk haplotype 
APOE e4 could be an important factor. Genome-wide association 
studies are designed to test single base variant associations, usu-
ally employing additive models. Additional analyses are therefore 
needed to analyze complex haplotypes like those of APOE, com-
bining 2 separate variants and requiring genotype-based analyses 
with no presumption of the inheritance mode, which are not part 
of the standard GWAS analysis. We therefore undertook this add-
itional analysis, with no risk of undermining the GWAS effort for 
COVID-19.
The authors point out that the APOE e4e4 association we 
reported reached genome-wide significance (p < 5 × 10–8) in our 
second analysis after additional data became available, but not 
in the first. We agree that under normal circumstances, it would 
not have been ideal to publish non-genome-wide significant re-
sults, at least without strong a priori evidence. However, at the 
time of writing, data on COVID-19 host genetics were extremely 
scarce, and given the global health emergency created by the pan-
demic, and the importance of dementia as a risk factor for severe 
COVID-19, we believe our work was a useful contribution, with 
early publication inviting others to examine this potential risk 
mechanism.
The second issue raised by Nikogosov et al. relates to the UK 
Biobank providing data on whether the patients tested for COVID-
19 were hospital inpatients, and suggesting that the valid com-
parison should have been between inpatient positives and positives 
not admitted to hospital. However, the data available at the time 
were actually derived from the test samples sent to laboratories, 
stating only where the patient was when the test sample was taken 
(4). Thus, patients may have been recorded as being in a non-
inpatient setting when tested but could have been admitted to hos-
pital soon after. Therefore, the suggested design from Nikogosov 
et  al. would not have been measuring what they suggest, likely 
biasing the association to the null (5). We note that the only pub-
lished GWAS to date compared cases with respiratory failure to 
convenient controls regardless of COVID-19 test results, including 
blood donors randomly selected for the study and genotyped con-
trols from previous studies (6). Our comparison with the rest of the 
UK Biobank participants (negative/unknown), therefore, provided a 
less-selected control group without evidence of COVID-19 and had 
better statistical power compared to the outcome of inpatient posi-
tives versus non-inpatient positives.
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